Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Firebrick Pharma Limited ( (AU:FRE) ) has shared an announcement.
Firebrick Pharma reported significant progress in the March 2026 quarter, highlighted by regulatory approval of its Nasodine Nasal Spray in Indonesia, Southeast Asia’s largest market, and the launch of Nasodine Throat Spray in Singapore and Fiji via local partners. These developments, coupled with strong early demand from healthcare professionals, advance the company’s goal of scaling from two products in three countries to four products in up to 10 markets over the next three years.
To support this expansion, Firebrick strengthened its leadership with the appointment of North America–based industry veteran Al Moghaddam as a non-executive director and deal-making specialist Nilesh Wadhwa as head of business development and licensing, while securing $1.5 million in fresh equity to provide a 12-month funding runway. Operating expenses rose due to one-off regulatory, business development and recruitment costs, but are expected to normalise, positioning the company for continued international growth and potential new approvals, including in the Philippines.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising over-the-counter antiviral nasal and throat sprays, led by its Nasodine-branded products. The company targets international markets, particularly in Asia-Pacific and North America, through licensing partnerships and a strategy to expand its product range and geographic reach.
Average Trading Volume: 91,873
Technical Sentiment Signal: Buy
Current Market Cap: A$18.37M
See more data about FRE stock on TipRanks’ Stock Analysis page.